Peripherally inserted central catheters (PICC) use in patients with chronic kidney disease (CKD)

Sonia Yaqub  
*Aga Khan University, sonia.yaqub@aku.edu*

Muhammad Raheel Abdul Razzaque  
*Aga Khan University*

Follow this and additional works at: [https://ecommons.aku.edu/pakistan_fhs_mc_med_nephrol](https://ecommons.aku.edu/pakistan_fhs_mc_med_nephrol)

Part of the Nephrology Commons

**Recommended Citation**  
Available at: [https://ecommons.aku.edu/pakistan_fhs_mc_med_nephrol/65](https://ecommons.aku.edu/pakistan_fhs_mc_med_nephrol/65)
Peripherally inserted central catheters (PICC) use in patients with chronic kidney disease (CKD)

Sonia Yaqub, Muhammad Raheel Abdul Razzaque

Madam, the use of peripherally inserted central catheters (PICC) has expanded rapidly in recent years. PICCs are perceived to be a safe and effective form of venous access with certain advantages over others such as ease of placement, lower rate of complications compared to non-tunneled central venous catheters, and longevity allowing home administration of drugs. However, a large number of complications associated with PICCs are being recognized increasingly such as thromboembolism and trauma to the vessels eventually causing central venous stenosis. This can have very significant implications for patients suffering from chronic kidney disease (CKD) who are at risk for progression to kidney failure and eventually require haemodialysis (HD).1 It is of paramount importance to maintain integrity of veins to provide a future haemodialysis vascular access for these patients. PICC lines may cause local trauma to vessels and hence may preclude future vascular access creation and its longevity. Due to multiple comorbid conditions, patients with CKD are more likely to have PICCs potentially increasing their risk for loss of veins.2 A strong and independent association between PICC use and lack of a functioning arterio-venous fistula has been proven in a case-control study of HD patients.3 Guidelines have been developed by various societies to prevent future access failure in CKD patients. The American Society of Nephrology, National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) and the Fistula First Breakthrough Initiative (FFBI) recommend against PICC use in patients at risk for or with known stage 3, stage 4 or 5 CKD without consulting a nephrologist.4-6

It is essential to understand that vein protection must begin long before initiation of HD is needed. It cannot be over emphasized that the potential long-term consequences of the PICCs must be weighed against their short-term convenience in CKD patients. The ultimate responsibility lies with nephrology community to educate non-nephrologist clinicians about the need to have vein protection strategies aimed at preserving future HD access. Moreover, given the fact that PICC insertion occurs most commonly in the hospital setting, there is a pressing need to apprise the practitioners/clinicians of careful selection of patients. Furthermore, there is a need for the interventionists who place the lines to be aware of and to adhere to aforementioned guidelines. At institutional level, policies and protocols that require nephrology consultation for any PICC request in patients with CKD may be considered and implemented. This may require a collaborative approach among physicians from various specialties and could be facilitated with electronic alerts in hospitals where electronic health records are in use. Last but not the least, awareness needs to be created among patients suffering from CKD and their family members about the potential risks and avoidance of PICCs.

Disclaimer: None to declare.

Conflict of Interest: None to declare.

Funding Disclosure: None to declare.

References

https://doi.org/10.5455/JPMA.55207

Department of Medicine, Aga Khan University Karachi, Pakistan.
Correspondence: Sonia Yaqub. Email: sonia.yaqub@aku.edu